American Shared Hospital ServicesAMS
Recorded

American Shared Hospital Services 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration27 minParticipants7

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good afternoon, and welcome to the American Shared Hospital Services Third Quarter 2026 Earnings Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then two. Please note, this event is being recorded. I would now like to turn the conference over to Kirin Smith, Investor Relations.

Kirin SmithPresident and Investor Relations Representative

Please go ahead. Thank you, Gary, and thank you everyone for joining us today.

Kirin SmithPresident and Investor Relations Representative

AMS's Third Quarter 2026 Earnings Press Release was issued earlier today. If you need a copy, it can be accessed on the company's website at www.ashs.com under the Investors section. Before turning the call over to management, I would like to make the following remarks concerning forward-looking statements. Please note that various remarks that may be made on this conference call about future expectations, plans, and prospects for the company constitute forward-looking statements for the purposes of safe harbor provisions under the Private Securities Litigation Reform Act of 1995.

Kirin SmithPresident and Investor Relations Representative

Actual results may vary materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the company's filings with the SEC, including the company's annual report and Form 10-K for the year ended December 31, 2025, and Form 10-Qs for the quarters ended June 30, 2026, and March 31, 2026. The company assumes no obligation to update the information contained in this conference call. Before I turn the call over to management, I'd like to remind everyone about our Q&A policy, where we provide each participant the time to ask one question and one follow-up. As always, we'll be happy to take additional questions offline. With that, I'd now like to turn the call over to Ray Stachowiak, Executive Chairman.

Ray StachowiakExecutive Chairman

Ray, please go ahead. Thank you, Kirin, and thank you all for joining us today.

Ray StachowiakExecutive Chairman

I'll begin with an update on our strategic priorities and then provide some perspective on the company's operating performance, growth opportunities, and financial position. During the first nine months of fiscal 2026, we continue to make progress in expanding our Direct Patient Services business while maintaining our established Medical Equipment Leasing operations. Total revenue increased approximately 14% year-over-year, with Direct Patient Services revenue increasing approximately 27%. This growth reflects the continued contribution of our Rhode Island operations and our international facilities. Our strategy remains focused on building a stronger, more diversified business with a greater emphasis on Direct Patient Services. We believe this approach provides opportunities to participate more directly in the delivery of specialized radiation therapy services while leveraging our experience and longstanding relationships in the medical technology industry.

Ray StachowiakExecutive Chairman

We continue to see opportunities across our existing operations. Our Gamma Knife facilities in Peru and Ecuador have contributed to growth in patient procedures, while our Rhode Island operations remain an important part of our Direct Patient Services platform. We are also continuing to advance our international development initiatives. One important opportunity is our joint venture with Hospital San Javier in Guadalajara, Mexico. We currently expect the facility to begin treating patients in mid-2027. We believe this project represents an opportunity to expand our presence in an important market and build on our experience operating specialized radiation therapy facilities. At the same time, we continue to focus on our capital structure and evaluate alternatives. We have been working with our lenders and other stakeholders to address these matters.

Ray StachowiakExecutive Chairman

Our current financing arrangements require continued attention and execution against specified milestones, and we are focused on navigating through these while enhancing the value of our operating businesses and pursuing opportunities for long-term growth. As discussed on our last call, I formed a new company several months ago that purchased additional shares from a private investor. In addition, this new company also invested $2 million of subordinated finance in this past quarter, which reflects my continued confidence in the overall company and provides additional financial flexibility as we move forward. Clearly, we have valuable assets, experienced personnel, and meaningful opportunities to expand our Direct Patient Services platform. Our priority is to translate those strengths into sustainable operating performance and improved financial results. I remain excited about our future prospects and the growth opportunities, and my commitment to enhancing shareholder value remains as strong as ever.

Ray StachowiakExecutive Chairman

With that, I will turn the call over to Craig Tagawa, our Interim Chief Executive Officer, to discuss the company's operating performance and business developments in greater detail.

Craig TagawaInterim CEO

Craig? Thank you, Ray, and thank you everyone for joining us today.

Craig TagawaInterim CEO

As Ray mentioned, we made continued progress in growing our Direct Patient Services business during the first nine months of fiscal 2026. For the third quarter, total revenue increased 6.3% to approximately $7.6 million, compared with approximately $7.2 million in the prior year period. For the first nine months, revenue increased 13.7% to approximately $23.1 million, compared with approximately $20.4 million last year. The primary driver of this growth was our Direct Patient Services segment. Third quarter revenue from the segment increased approximately 14% to $4.6 million, while nine-month revenue increased 27% to $13.5 million. Our Direct Patient Services operations include our radiation therapy facilities in Rhode Island and Puebla, Mexico, as well as our Gamma Knife facilities in Peru and Ecuador. Our international Gamma Knife operations continue to perform well.

Craig TagawaInterim CEO

Total Gamma Knife procedures increased approximately 11% in both the third quarter and first nine months compared with the prior year periods. In Peru, the upgrade to the Leksell Gamma Knife Esprit system has supported improved treatment efficiency, resulting in shorter treatment times. We believe this investment has strengthened the facility's ability to serve patients and support future growth. In Rhode Island, our radiation therapy operations remain an important component of the Direct Patient Services business. Revenue from the Rhode Island and Puebla radiation therapy facilities increased both the third quarter and nine-month periods. While procedure volumes at these facilities were somewhat lower compared with the prior year periods, revenue increased, reflecting the overall contribution of these operations to the segment. Our Proton Beam Radiation Therapy system also continues to be an important part of our business.

Craig TagawaInterim CEO

Revenue from the PBRT system was lower in the third quarter compared with the prior year period, although revenue for the first nine months increased. Procedure volumes can fluctuate from quarter to quarter based on treatment scheduling and other factors, and we continue to focus on supporting utilization of this specialized asset. Our Medical Equipment Leasing segment generated approximately $3 million in third quarter revenue and $9.6 million for the first nine months. While revenue was modestly lower compared with the prior year periods, the segment continues to provide an established base of recurring revenue from our equipment leasing relationships. Operationally, our priorities remain focused on improving utilization at our facilities, supporting clinical and administrative teams, strengthening referrals relationships, and improving revenue cycle execution. We are also continuing to evaluate opportunities to improve operating efficiency and managing costs across the organization.

Craig TagawaInterim CEO

We recognize that the financial performance of our Direct Patient Services facilities can be affected by reimbursement levels, procedure volumes, staffing, maintenance costs, and local market conditions. We remain focused on managing these factors while continuing to build the platform for future growth. Looking ahead, we believe our Direct Patient Services operations provides an important opportunity to expand our participation in specialized radiation therapy markets. We will continue to focus on operational execution, prudent investment, and improving the financial performance of our existing facilities. I'll now turn the call over to Alexis Wallace, our Interim Chief Financial Officer and Chief Accounting Officer, to review the financial results in more detail.

Alexis WallaceInterim CFO and Chief Accounting Officer

Thank you, Craig, and good day, everyone. I'll start with a review of our financial results for the third quarter and first nine months of fiscal 2026, and then turn to our balance sheet and liquidity position. Total revenue for the third quarter ended September 30, 2026, was approximately $7.6 million, compared with approximately $7.2 million in the third quarter of the prior year, an increase of approximately $453,000 or 6.3%. Revenue from our Direct Patient Services segment increased approximately $549,000 or 13.6% to $4.6 million. This increase was primarily attributable to higher revenue from our Rhode Island radiation therapy facilities and our international Gamma Knife operations. Revenue from our Medical Equipment Leasing segment was approximately $3 million, compared with approximately $3.1 million in the prior year quarter. Gross profit for the quarter was approximately $1.5 million, compared with approximately $1.6 million in the prior year period.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day